Drugs / sitokiren
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03255993 | Oct 2017 → Sep 2018 | hypertensive disorder | Shanghai Pharmaceuticals Holding Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT03249753 | Sep 2017 → Sep 2018 | hypertensive disorder | Shanghai Pharmaceuticals Holding Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT03128138 | Dec 2016 → Jun 2018 | hypertensive disorder | Shanghai Pharmaceuticals Holding Co., Ltd | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05593562 | Oct 2022 | essential hypertension | Shanghai Pharmaceuticals Holding Co., Ltd | Completed | No outcome recorded |
| Phase 1/2 | NCT05359055 | Dec 2021 → Jan 2022 | — | Shanghai Pharmaceuticals Holding Co., Ltd | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT05770609 | Jun 2023 → Sep 2024 | ulcerative colitis | Shanghai Pharmaceuticals Holding Co., Ltd | Completed | No outcome recorded |
| Phase 2 | NCT05593575 | Mar 2023 → Dec 2024 | diabetic kidney disease | Shanghai Pharmaceuticals Holding Co., Ltd | Completed | No outcome recorded |
| Phase 2 | NCT05019742 | Mar → Nov 2022 | ulcerative colitis | Shanghai Pharma Biotherapeutics USA Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT03756103 | Jan 2019 → Jun 2020 | essential hypertension | Shanghai Pharmaceuticals Holding Co., Ltd | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05359068 | Jun 2021 → Dec 2023 | essential hypertension | Shanghai Pharmaceuticals Holding Co., Ltd | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | sitokiren | “To evaluate the efficacy and safety of sitokiren (SPH3127) tablet in patients with mild-to-moderate essential hypertension in comparison to valsartan capsule.” PMID 42165988 ↗ May 2026 |
| Known as | SITOKIRENE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4110551 ↗ |
| Known as | SITOKIRENO | ChEMBL registry synonym — accepted as the source's own label CHEMBL4110551 ↗ |
| Known as | SPH3127 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03249753 ↗ |
| Action | Inhibit | “plasma renin activity inhibition of up to 90%” PMID 33653620 ↗ Feb 2021 |
| Modality | Small molecule | — CHEMBL4110551 ↗ |
| Route | Oral | “single oral dose” NCT03128138 ↗ |
| Target | REN | “a Novel Direct Renin Inhibitor” PMID 42165988 ↗ May 2026 |